Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.
Watanabe T, Terui S, Itoh K, Terauchi T, Igarashi T, Usubuchi N, Nakata M, Nawano S, Sekiguchi N, Kusumoto S, Tanimoto K, Kobayashi Y, Endo K, Seriu T, Hayashi M, Tobinai K.
Watanabe T, et al. Among authors: kusumoto s.
Cancer Sci. 2005 Dec;96(12):903-10. doi: 10.1111/j.1349-7006.2005.00120.x.
Cancer Sci. 2005.
PMID: 16367911
Free PMC article.
Clinical Trial.